Potential hit for Cipla from US animal health patent case?
This article was originally published in Scrip
A US appeals court has upheld a previous order against Cipla in a case concerning the Indian firm's generic version of FrontLine Plus, a companion animal antiparasitic brand marketed by Sanofi's animal health division Merial.
You may also be interested in...
Aurobindo and Sandoz mutually terminate their planned $1bn deal, leaving many questions on how both sides will re-orient strategies going forward.
Takeda appoints new country head for India and aims to improve patient access to innovative medicines in the largely out-of-pocket market.
The coronavirus pandemic has thrown up unprecedented challenges for the Indian clinical trials segment, as in other parts of the world. Experts tell Scrip how things are poised in the country including potential impact on some critical milestones, but efforts are underway to tackle the crisis.